te any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.
About Milliman
Milliman is among the world's largest independent actuarial and consulting firms. Founded in Seattle in 1947 as Milliman & Robertson, the company currently has 49 offices in key locations worldwide. Milliman employs more than 2000 people, with a professional staff of more than 1000 qualified consultants and actuaries, including specialists ranging from clinicians to economists. The firm has consulting practices in healthcare, employee benefits, property and casualty insurance, life insurance, and financial services. Milliman serves the full spectrum of business, financial, government, union, education, and nonprofit organizations. For further information, visit www.milliman.com.
'/>"/>SOURCE Medco Health Solutions, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine news :1.
New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 2.
Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams3.
Shining light on sciences dark data: New venture ensures a fuller scientific record4.
New Government Data: Mail-Service Pharmacies Grow, But Public Programs Lag Behind5.
Five Hospitals to Share Patient Data: ICW Connects Regional Medical Centers and University Facility6.
Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD7.
Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer8.
Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer9.
Advanced lung cancer patients see improved, progression-free survival10.
Advanced Imaging Technologies to Limit Breast and GI Biopsy Procedures11.
Unilens Launches New C-VUE(R) Advanced(TM) Custom Toric Lens